Transfection Reagents and Equipment Market Share by 2030

Transfection Reagents and Equipment Market Size and Forecast (2020 - 2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Product (Reagents and Instruments), Method (Viral Methods, Non Viral Methods, and Hybrid Methods), Application (Biomedical Research, Protein Production, and Therapeutic Delivery), End User (Academics & Research Institutes and Pharmaceutical & Biotechnology Companies), and Geography

Publication Month : Jan 2024

  • Report Code : TIPHE100001124
  • Category : Medical Device
  • Status : Published
  • No. of Pages : 241
Inquire Before Buy

PRICING

$5190

$4152

[Research Report] Transfection reagents and equipment market is expected to grow from US$ 1,170.79 million in 2022 to US$ 2,145.03 million by 2030; it is anticipated to record a CAGR of 7.8% from 2022 to 2030.

Market Insights and Analyst View:

The expansion of the transfection reagents and equipment market size is attributed to the rising cases of chronic diseases, and the surging popularity of cell and gene therapy. Transfection is the process of transferring foreign particles and nucleic acids into cells through chemical, physical, and biological means. Transfection reagents are used to improve the efficacy of genetic experiments performed as a part of substantial research conducted in the fields of applied gene therapies. In all transfection experiments, the methods by which compounds are delivered into cells must be carefully chosen. Viral-mediated transfection has demonstrated considerable effectiveness, and the transfected products can induce significant immune responses. However, chemical alternatives have been developed to curb the ill effects associated with the use of viruses in the technique.

Growth Drivers and Challenges:

Cell and gene therapy manufacturing is a complicated process, which makes its execution and monitoring critical. Advancements in biotechnology have led to the adoption of personalized treatments for the treatment of numerous indications. Cell and gene therapies are mostly used to treat chronic diseases such as neurological disorders, cancer, and genetic disorders. The noteworthy advantages of cell and gene therapy include targeted treatment, faster and more efficient recovery, and reduced side effects. Cell and gene therapies are widely adopted worldwide owing to the availability of Food and Drug Administration (FDA) approved products. For instance, the FDA approved an adenovirus, ADSTILADRIN, manufactured by Ferring Pharmaceuticals A/S in 2022. This recombinant adenovirus (rAd-IFNa/Syn3) delivers human interferon alfa-2b cDNA into the bladder epithelium to treat patients suffering from certain types of bladder cancer. In 2022, the FDA approved CARVYKTI, manufactured by Janssen Biotech, Inc.. CARVYKTI is an autologous CAR-T cell engineered with lentivirus to attack BCMA-expressing tumor cells to treat certain kinds of relapsed or refractory multiple myeloma.

According to the article “Gene therapy process change evaluation framework: Transient transfection and stable producer cell line comparison," published by the University College London (UCL) in 2020, 423 ongoing clinical trials were conducted to test gene therapy products. Scientists nowadays employ the transfection technique for the production of these therapies. Hence, an upsurge in the popularity of cell and gene therapy activities fuels the number of transfection procedures performed, which, in turn, fuels the growth of the transfection reagents and equipment market

Ongoing efforts to develop approaches to ramp up the small-scale transfection processes act as an opportunity to grow the transfection reagents and equipment market. Transfection is the complex step in developing a viral vector, including adenovirus, adeno-associated virus, and lentivirus. Transient transfection must also be ramped up as the manufacturing processes are scaled up. Process equipment vendors, drug developers, and raw material suppliers are focusing on collaborations to develop cost-effective, practical, and platformizable solutions for rapidly developing and scaling up viral vector manufacturing processes. With planned material volumes and transfer & mixing times, transfecting cells with multiple plasmids becomes feasible on small scales. Scaling up requires experience in industrializing the transfection step since most companies only have transfection experience at the lab level. However, the volume of cell-culture media and transfection reagents required for scaling up the process to a larger level can be impractical, emphasizing the need for optimization.

Nonetheless, broadening the production scale has become common in recent years with the surging demand for viral vectors. With numerous challenges associated with large-scale transfection processes, the best approach to increase production is reducing the process rather than scaling up the process. This top-down approach allows clear identification of the conditions that will impact the process at the industrial level, such as the volume of transfection complex solution. This approach also facilitates process optimization and decision-making.

Customize Research To Suit Your Requirement

We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.

Transfection Reagents and Equipment Market: Strategic Insights

transfection-reagents-and-equipment-market
Market Size Value inUS$ 1,170.79 million in 2022
Market Size Value byUS$ 2,145.03 million by 2030
Growth rateCAGR of 7.8% from 2022 to 2030
Forecast Period2022-2030
Base Year2022
Analyst Image

Akshay

Have a question?

Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.

Analyst Image  Speak to Analyst

Report Segmentation and Scope:

The transfection reagents and equipment market is fragmented based on product, modality, application, end user, and geography. Based on product, the market is classified into reagents and equipment. Based on modality, the transfection reagents and equipment market is classified into viral, non-viral, and hybrid methods. In terms of application, the transfection reagents and equipment market is classified into biomedical research, protein production, and therapeutic delivery. The transfection reagents and equipment market, by end-user, is classified into academic and research institutes and pharmaceutical and biotechnological companies. Based on geography, the transfection reagents and equipment market is segmented into North America (US, Canada, and Mexico), Europe (UK, Germany, France, Italy, Spain, Russia, and Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, Southeast Asia, and Rest of Asia Pacific), the Middle East & Africa (UAE, Saudi Arabia, South Africa, and Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and Rest of South & Central America).

  • Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
  • Request discounts available for Start-Ups & Universities

Segmental Analysis:

In 2022, the non-viral methods segment, based on modality, held a larger share of the transfection reagents and equipment market. The non-viral methods segment will record a higher CAGR from 2022 to 2030. The non-viral-based transfection approach can be further classified into physical/mechanical and chemical methods. Popular physical/mechanical transfection methods include electroporation, sonoporation, magnetofection, gene microinjection, and laser irradiation. Electroporation is a commonly used physical transfection method that uses electrical voltage to transiently increase the cell membrane permeability to allow the entry of foreign nucleic acid into cells. Ultrasound-assisted transfection or sonoporation involves using a microbubbles technique to create holes into the cell membrane to ease the transfer of genetic materials, while laser irradiation-assisted transfection uses a laser beam to create small holes in the plasma membrane to allow the entry of foreign genetic substances. Chemical transfection methods can be further categorized as liposomal-based or non-liposomal-based. Liposomal-based transfection reagents permit the formation of positively charged lipid aggregates that can smoothly combine with the phospholipid bilayer of host cells to permit the entry of foreign genetic materials with minimal resistance. Non-liposomal transfection reagents can be divided into several classes: calcium phosphate, dendrimers, polymers, nanoparticles, and non-liposomal lipids. Viral vector systems include retroviruses, adenoviruses (AdV), adenovirus-associated viruses (AAV), lentiviruses (LV), and bacteriophages. Most gene therapy drugs currently available on the market use viruses as vectors. Although viral vectors pose disadvantages such as high immunogenicity, safety hazards, and production difficulties, their higher transfection efficiencies present a unique advantage for gene delivery. Generally, retroviruses can only be used to transfect dividing cells, while adenoviruses, AAVs, and herpes viruses can be used to transfect dividing and non-dividing cells.

Transfection Reagents and Equipment Market, by Product – 2022 and 2030

  • Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
  • Request discounts available for Start-Ups & Universities

In 2022, the reagents segment, based on product, held a larger share of the transfection reagents and equipment market. The reagents segment will record a higher CAGR from 2022 to 2030. The demand for transfection reagents is increasing with an upsurge in product launches and the focus on scaling up the transfection process. In August 2021, Mirus Bio launched the TransIT VirusGEN GMP product line of transfection reagents and enhancers to support viral vector manufacturing for gene therapy development and related processes. The TransIT VirusGEN GMP transfection reagent was developed to enhance the delivery of transfer vaccine DNA to suspension and adherent HEK 293 cells to better the production of recombinant AAV and LV vectors. The growing focus on launching GMP-complaint transfecting reagents to enhance vectors' production capacity further fuels the market's progress for transfection reagents.

Based on application, the biomedical research segment held the largest share of the transfection reagents and equipment market in 2022. The market for this segment is expected to grow at the fastest CAGR during 2022–2030. The academic and research institutes segment accounted for a larger share of the transfection reagents and equipment market, by end-user, in 2022. The market for the pharmaceutical and biotechnological companies segment is expected to grow at a higher CAGR during 2022–2030.

Regional Analysis:

Based on geography, the transfection reagents and equipment market is divided into North America, Europe, Asia Pacific, the Middle East & Africa, and South & Central America. North America is the largest contributor to the global transfection reagents and equipment market growth. Asia Pacific is expected to register the highest CAGR in the transfection reagents and equipment market from 2022 to 2030. Cell and gene therapies (CGTs) are prescribed to treat patients suffering from serious and rare diseases with unaddressed therapeutic needs. Manufacturing CGTs is a highly complex process, with insufficient infrastructure and expertise being a major limiting factor. Logistics-related challenges associated with intermediates and final products limit companies' CGT manufacturing capacity. The CGT manufacturing process involves extracting autologous cells through "apheresis," dispatching them to specialized laboratories, and sending them back to clinics for patient administration, all of which must be performed with strict quality control. The US Food and Drug Administration (FDA) has approved only 7 CGT drugs so far, and the pipeline of new products has reached ~1,200 experimental therapies. Half of these are in Phase 2 clinical trials. With these prospects, annual sales of cell and gene therapies are estimated to grow by 15% and ~30%, respectively, as stated in the Chemical & Engineering News Report 2023.

Many manufacturers approach contract development manufacturing organizations (CDMOs) such as Labcorp, Lonza, and Catalent to overcome the barriers associated with the production and commercialization of their CGT products. Lonza has invested ~US$ 9.2 million to strengthen its cell and gene therapy manufacturing capabilities. Such initiatives by CDMOs are contributing to the growth of the transfection reagents and equipment market in the US.

Industry Developments and Future Opportunities:

One of the prominent initiative by key players operating in the Transfection Reagents and Equipment Market are listed below:

  1. In September 2023, Polyplus made the FectoVIR-LV transfection reagent for lentiviral vector (LV) synthesis available for pre-ordering. With this, the company also extended new design of experiment (DoE) services at no cost to optimize transfection conditions for better LV vector titers and quality in suspension systems. In suspension HEK-293 cell systems, FectoVIR-LV is a next-generation transfection that enhances LV production. The reagent has been engineered to reduce complexation volume and boost complex stability while maintaining its animal-free composition, making it suitable for large-scale production.

Competitive Landscape and Key Companies:

A few of the prominent players operating in the transfection reagents and equipment market are Thermo Fisher Scientific Inc., Promega Corporation, Qiagen N.V., Merck KGaA, Lonza Group, F.Hoffmann-La Roche Ltd, Bio-Rad Laboratories Inc., Mirus Bio LLC, MaxCyte Inc, and Polyplus-Transfection SA. These companies focus on new product launches and geographic expansions to meet the growing consumer demand worldwide and expand their product range with specialty portfolios. Their global presence allows them to serve a large base of customers, subsequently facilitating market expansion.

Report Coverage
Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
Segment Covered

Product, Method, Application, End User, and Geography

Regional Scope
Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
Country Scope

This text is related
to country scope.

Frequently Asked Questions


What is transfection reagents and equipment?

Transfection reagents are used to improve the efficacy of genetic experiments performed as a part of substantial research in applied gene therapies. In all transfection experiments, the methods by which compounds are delivered into cells must be carefully chosen. Viral-mediated transfection has demonstrated considerable effectiveness, and the transfected products can induce significant immune responses. However, chemical alternatives have been developed to curb the ill effects associated with the use of viruses in the technique.

What are the driving and restraining factors for the transfection reagents and equipment market?

The factors driving the market include the increasing popularity of cell and gene therapy and the growing economic burden of cancer. However, the high cost of instruments and consumables hinders the market growth.

Who are the major players in the transfection reagents and equipment market?

The transfection reagents and equipment market majorly consists of players such as Thermo Fisher Scientific Inc., Promega Corporation, Qiagen N.V., Merck KGaA, Lonza Group, F.Hoffmann-La Roche Ltd, Bio-Rad Laboratories Inc., Mirus Bio LLC, MaxCyte Inc, and Polyplus-Transfection SA.

Which segment is dominating the transfection reagents and equipment market?

The transfection reagents and equipment market is fragmented based on product, modality, application, end user, and geography. Based on product, the market is classified into reagents and equipment. In 2022, the reagents segment, based on product, held a larger share of the transfection reagents and equipment market. The reagents segment will record a higher CAGR from 2022 to 2030.




Based on modality, the transfection reagents and equipment market is classified into viral, non-viral, and hybrid methods. In 2022, the non-viral methods segment, based on modality, held a larger share of the transfection reagents and equipment market. The non-viral methods segment will record a higher CAGR from 2022 to 2030.

In terms of application, the transfection reagents and equipment market is classified into biomedical research, protein production, and therapeutic delivery. Based on application, the biomedical research segment held the largest share of the transfection reagents and equipment market in 2022. The market for this segment is expected to grow at the fastest CAGR from 2022 to 2030.

The transfection reagents and equipment market, by end-user, is classified into academic and research institutes and pharmaceutical and biotechnological companies. The academic and research institutes segment accounted for a larger share of the transfection reagents and equipment market, by end user, in 2022. The market for the pharmaceutical and biotechnological companies segment is expected to grow at a higher CAGR from 2022 to 2030.

Based on geography, the transfection reagents and equipment market is segmented into North America (the US, Canada, and Mexico), Europe (the UK, Germany, France, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific), the Middle East & Africa (the UAE, Saudi Arabia, South Africa, and Rest of the Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America). North America is the largest contributor to the global transfection reagents and equipment market growth. Asia Pacific is expected to register the highest CAGR in the transfection reagents and equipment market from 2022 to 2030.

The List of Companies - Transfection Reagents And Equipment Market

  1. Thermo Fisher Scientific Inc.
  2. Promega Corporation
  3. Qiagen N.V.
  4. Merck KGaA
  5. Lonza Group
  6. F.Hoffmann-La Roche Ltd
  7. Bio-Rad Laboratories Inc.
  8. Mirus Bio LLC
  9. MaxCyte Inc
  10. Polyplus-Transfection SA.

The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

  1. Data Collection and Secondary Research:

As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.

  1. Primary Research:

The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

A typical research interview fulfils the following functions:

  • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
  • Validates and strengthens in-house secondary research findings
  • Develops the analysis team’s expertise and market understanding

Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

  • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
  • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

Below is the breakup of our primary respondents by company, designation, and region:

Research Methodology

Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

  1. Data Analysis:

Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

  • 3.1 Macro-Economic Factor Analysis:

We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

  • 3.2 Country Level Data:

Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

  • 3.3 Company Profile:

The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

  • 3.4 Developing Base Number:

Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

  1. Data Triangulation and Final Review:

The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Trends and growth analysis reports related to Transfection Reagents and Equipment Market